SUV was calculated using the formula; SUV=concentration of radioactivity in volume of interest (VOI) (MBq/mL)×lean body weight/injected radioactivity (g/MBq). Metabolic parameters including SUVmax, metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were measured by a board certified nuclear medicine physician with 14 years of PET experience who was blinded to patient information. Implanted software packages were used to measure metabolic parameters (Advantage Workstation, GE Healthcare, or TrueD, Siemens Healthcare). Primary tumor boundaries were delineated using SUV thresholds of 2.5 and 3.0 [18 (link)19 (link)]. VOIs were drawn to include the entire UCS. MTV2.5 and MTV3.0 were defined as the sum of voxel volumes with SUV of ≥2.5 and ≥3.0 within a given VOI, respectively. TLG2.5 and TLG3.0 were calculated as MTV2.5 and MTV3.0 multiplied by the average SUV of voxels, respectively. In patients where the tumor had no hypermetabolic activity above the SUV threshold within the uterus, MTV and TLG of the primary tumor were considered as zero. All VOIs were checked slice by slice on transaxial and coronal planes to check whether the physiologic uptake of bowel and ovary or urine activity included. When the physiologic uptakes were included, region of interest (ROI) were manually drawn slice by slice and MTV were calculated again within the predefined sum of ROIs.
Trued
Manufactured by Siemens
Sourced in Germany
The TrueD is a high-precision laser-based measurement system designed for industrial applications. It provides accurate and reliable dimensional measurements for quality control, process monitoring, and product development. The TrueD utilizes advanced laser technology to capture detailed 3D data without physical contact with the measured object.
Automatically generated - may contain errors
6 protocols using trued
1
Metabolic Parameters in Uterine Carcinosarcoma
2
Multimodal Imaging for Metastatic Cancer
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Image fusion of PET and CT data and evaluation of the separate CT and PET as well as fused PET/CT images were performed on a dedicated PET/CT workstation (TrueD, Siemens Health Care, Erlangen, Germany). Two experienced readers (specialists in radiology and nuclear medicine) evaluated CT and PET images separately, as well as the fused PET/CT images. This was done in a consensus mode for the presence of regional and distant metastases, as well as the extent of the primary tumor at the initial examination. For study purposes, a secondary analysis of CT and PET as well as merged PET/CT images was performed by a radiologist with 12 years of experience in oncologic imaging. To compare the diagnostic yield of CT and PET/CT, contrast-enhanced CT images of the PET/CT examination were assessed prior to reading the merged PET/CT image series to prevent a bias arising from the knowledge of the PET findings. Using CT data from the PET/CT examination ensures comparable disease stage, because acquisition took place at the same time.
3
Whole-Body 18F-FDG PET/CT Imaging Protocol
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Patients were instructed to fast for > 4 h before the PET/CT examination. Images of the whole body were acquired 40–60 min after 18F-FDG (0.15 mCi/kg) was injected. The PET/CT datasets were reconstructed automatically, and attenuation correction was performed with CT attenuation. The results were measured using the software on the PET/CT system workstation (TrueD, Siemens Medical Systems).
4
Quantitative PET/CT Image Analysis
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
An experienced nuclear medicine physician has visually and semi-quantitatively analyzed 18F-FDG PET/CT images. A region of interest (ROI) was drawn around the tumor to calculate SUVmax and mean SUV (SUVmean) values. A volume of interest with an SUV threshold of 2.5 was used to determine the MTV using the software program (TRUE D, Siemens Medical Solutions). TLG was obtained by multiplying the MTV by the SUVmean.
5
PET-CT Evaluation of Esophageal Tumors
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
One certified nuclear medicine physician evaluated PET-CT in consideration of chest CT scan results before treatment. In this study, the FDG uptake was evaluated to be positive or negative by visual evaluation. It was defined positive when the primary lesion was visualized or could be distinguished from the background. On the other hand, the opposite was defined negative. The 3-dimensional image was made in the standardized uptake value (SUV) mode for semiquantitative evaluation on a workstation (syngo MultiModality Workplace, Siemens Healthcare, Erlangen, Germany; software program TrueD, Siemens Healthcare; soft workstation, Siemens, Medical Solutions). FDG uptake was automatically calculated as SUV by the following formula: SUV = tissue concentration (Bq/g)/ [injection dose (Bq)/body weight (g)]. The maximum SUV (SUVmax) of the primary esophageal tumor was automatically obtained from a region of interest, designated as a site of abnormal accumulation on the 3-dimensional images.
6
PET/CT Imaging of Tumor Angiogenesis
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
18 F-FDG PET/CT scan was conducted to assess the response to apatinib. Briefly, patients were instructed to avoid strenuous work or exercise for at least 1 day and fast for >4 h before the 18 F-FDG (0.15 mCi/kg) injection. After injection, patients rested in a warm, dark room for 40-60 min.
68 Ga-NOTA-PRGD2 was synthesised using the method described elsewhere (Zheng et al. 2015) (link). The radiochemical purity of the product 68 Ga-NOTA-PRGD2 exceeded 95%. After intravenous injection of 111-185 MBq (3-5 mCi) of 68 Ga-NOTA-PRGD2, patients were asked to rest for nearly 40 min. The PET acquisitions were performed 1 h after the injection.
The acquisition was performed from skull to midthigh (five to six beds position, 2 min per bed) using a Siemens Biograph 64 Truepoint TrueV PET/CT scanner.
The PET/CT data sets were reconstructed using iterative reconstruction (ordered subset expectation maximum, OSEM) and attenuation correction. The results were measured using the software on the PET/CT system's workstation (TrueD, Siemens Medical Systems) .
68 Ga-NOTA-PRGD2 was synthesised using the method described elsewhere (Zheng et al. 2015) (link). The radiochemical purity of the product 68 Ga-NOTA-PRGD2 exceeded 95%. After intravenous injection of 111-185 MBq (3-5 mCi) of 68 Ga-NOTA-PRGD2, patients were asked to rest for nearly 40 min. The PET acquisitions were performed 1 h after the injection.
The acquisition was performed from skull to midthigh (five to six beds position, 2 min per bed) using a Siemens Biograph 64 Truepoint TrueV PET/CT scanner.
The PET/CT data sets were reconstructed using iterative reconstruction (ordered subset expectation maximum, OSEM) and attenuation correction. The results were measured using the software on the PET/CT system's workstation (TrueD, Siemens Medical Systems) .
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!